a total of 90 days to submit data, analyses, and other relevant information.

Although the agency has reviewed the requests asking for extensions of the comment period, the longest of which is for an additional 1 year, FDA does not believe that such a lengthy delay is in the best interest of the public health. FDA believes that delaying the receipt of comments for more than an additional 45 days (for a total of 90 days) is too long given the public health concerns at issue.

II. How to Submit Comments

Interested persons may, on or before July 3, 2000, submit written comments to the Dockets Management Branch (address above). You may also send comments to the Dockets Management Branch via e-mail to

"FDADockets@oc.fda.gov". You should annotate and organize your comments to identify the specific issues to which they refer. You must submit two copies of comments, identified with the docket number found in brackets in the heading of this document, except that you may submit one copy if you are an individual. You may review received comments in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

Dated: May 16, 2000.

Margaret M. Dotzel,

Acting Associate Commissioner for Policy. [FR Doc. 00–12749 Filed 5–19–00; 8:45 am] BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Blood Products Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Blood Products Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on June 15, 2000, from 8 a.m. to 5 p.m. and on June 16, 2000, from 9 a.m. to 12:30 p.m.

Location: Holiday Inn, 8777 Georgia Ave., Silver Spring, MD.

Contact Person: Linda A. Smallwood, Center for Biologics Evaluation and Research (HFM–302), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852–1448, 301–827–3514, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 19516. Please call the Information Line for up-to-date information on this meeting.

Agenda: On June 15, 2000, the committee will hear updates on summaries of the Public Health Service Advisory Committee on Blood Safety and Availability meeting, April 25 and 26, 2000; FDA's Transmissible Spongiform Encephalopathies Advisory Committee meeting, June 1 and 2, 2000; the FDA-sponsored workshop on plasticizers, October 18, 1999; and a briefing on blood supply monitoring. The committee will also hear presentations and provide recommendations on plasma pool screening by nucleic acid tests for Hepatitis A virus and, in the afternoon, the committee will hear presentations and provide recommendations on the development of rapid human immunodeficiency virus (HIV) tests. On June 16, 2000, the committee will hear updates on the requirements for syphilis testing, the risk of Hepatitis C virus to sexual partners, and relative sensitivity of Hepatitis B surface antigen and Hepatitis B virus nucleic acid tests. Also, the committee will hear and discuss presentations on the proposed document entitled "FDA Guidance on Universal Leukoreduction: Current Thinking.'

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by Friday, June 2, 2000. Oral presentations from the public will be scheduled between approximately 11 a.m. to 11:30 a.m. and 2:30 p.m. to 3:30 p.m. on June 15, 2000, and between approximately 10:30 a.m. to 11:30 a.m. on June 16, 2000. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before Friday, June 9, 2000, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Dated: May 11, 2000.

Linda A. Suydam,

Senior Associate Commissioner. [FR Doc. 00–12747 Filed 5–19–00; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Agency Information Collection Activities: Submission for OMB Review; Comment Request

Periodically, the Health Resources and Services Administration (HRSA) publishes abstracts of information collection requests under review by the Office of Management and Budget, in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35). To request a copy of the clearance requests submitted to OMB for review, call the HRSA Reports Clearance Office on (301)–443–1129.

The following request has been submitted to the Office of Management and Budget for review under the Paperwork Reduction Act of 1995:

Proposed Project: The Black Lung Clinic Program Guidelines (42 CFR 55a) (OMB No. 0915–0081) Extension

The purpose of the Black Lung Clinics Program (BLCP) is to stimulate and encourage local public and private agencies to improve the health status of coal workers and to increase coordination with other programs to assist the coal worker population. The goal of the BLCP is to provide services to minimize the effects of respiratory and pulmonary impairments of coal miners. Grantees provide specific diagnostic and treatment procedures required in the management of problems associated with black lung disease which improve the functional status, i.e., "quality of life", of the miner and reduces economic costs associated with morbidity and mortality arising from pulmonary diseases.

This request is for approval of the application requirements which are included in the program guidelines and the program regulation (42 CFR 55a.201 and 55a.301). Grantees must submit applications annually for continued grant support. The regulations outline the requirements for grant applications for States (55a.201) and entities other than States (55a.301). The program guidelines further elaborate on these requirements.

The grant application form is cleared under another OMB approval (OMB No.

0920–0428). The burden for completing the application is not reflected in the Black Lung clearance request because the burden is reported in the clearance of the application form. The current request for clearance includes one hour of burden, to keep the clearance of the program-specific application requirements on the OMB database.

Written comments and recommendations concerning the proposed information collection should be sent within 30 days of this notice to: Wendy A. Taylor, Human Resources and Housing Branch, Office of Management and Budget, New Executive Office Building, Room 10235, Washington, DC 20503.

Dated: May 16, 2000.

Jane Harrison,

Director, Division of Policy Review and Coordination.

[FR Doc. 00–12751 Filed 5–19–00; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Availability of the HRSA Preview: Cancellation of HIV/AIDS Programs, Special Projects of National Significance

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Cancellation of Notice of Availability of Funds.

SUMMARY: This notice rescinds the Notice of Availability of funds in notice FR Doc. 99–21257, Part II, in the issue of Wednesday, August 18, 1999 on the following page, 45016, in column 2, last line, "Special Projects of National Significance. In the table on page 45019, in the section HIV/AIDS Programs, under "Special Projects of National Significance (SPNS)." On page 45032, in column 3, from heading "Special Projects of National Significance (SPNS)" through to bottom of this column.

Dated: May 16, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00-12753 Filed 5-19-00; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Division of Transplantation Extramural Grant Program: Model Interventions To Increase Organ and Tissue Donation

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice of Availability of Funds.

SUMMARY: The Health Resources and Services Administration's (HRSA) Office of Special Programs (OSP), Division of Transplantation (DoT) announces that applications will be accepted for fiscal year (FY) 2000 for grants to support projects demonstrating model interventions to increase organ and tissue donation. The grant program will assist qualified organ procurement organizations (OPOs) and other private non-profit entities eligible for funds under Section 371(a)(3) of the Public Health Service (PHS) Act , 42 U.S.C. 273(a)(3), as amended. HRSA/OSP/DoT invites applications from consortia of institutions/organizations to participate in the FY 2000 grant program.

Availability of Funds

The estimated total funds available for the first year of support (direct and indirect costs) for all awards made under this grant program in FY 2000 will be up to \$1.5 million. HRSA anticipates funding 8–10 projects. It is anticipated that the cost range for each project year will be \$100,000-\$300,000 per award; however, projects that fall outside that range also will be considered. The total project period for applications submitted in response to this program announcement may not exceed three years.

Eligible Applicants

Eligible applicants are consortia consisting at a minimum of the following two types of organizations/ institutions: (1) At least one organization/institution with demonstrated expertise and experience in research and evaluation design and methods in the behavioral and social sciences; and (2) at least one organization/institution with demonstrated expertise and experience in organ donation, including but not limited to: OPOs, hospitals, and other health care organizations; national or regional associations; community-based service organizations; and public health or other government agencies. One member of each consortium shall serve as the primary applicant institution,

which is required to be a private non-profit institution.

DATES: A letter of intent to submit an application is requested by June 8, 2000. Applications for this announced grant must be postmarked no later than July 11, 2000 to be considered for competition. Applications shall be considered as meeting the deadline if they are: (1) received on or before the deadline date; or (2) postmarked on or before the deadline date and received in time for orderly processing and submission to the review committee. Applications received with a postmark after 7-11-2000 will not be accepted. **ADDRESSES:** Application kits, which include detailed instructions, are available through the HRSA Grant Application Center (telephone: 1-877-477-2123, or e-mail: hrsagac@hrsa.gov). The program announcement also can be obtained by accessing any of the following three Web sites: www.hrsa.gov, www.hrsa.gov/osp/dot, or www.organdonor.gov. Letters of intent to submit an application should be mailed to Dr. Mary L. Ganikos, Chief, Education Branch, DoT, OSP, HRSA, 5600 Fishers Lane, Parklawn Building, Room 7C-22, Rockville, Maryland 20857. All applications must be mailed or delivered to HRSA Grants Application Center, 1815 N. Fort Meyer Drive, Suite 300 Arlington, VA 22209.

FOR FURTHER INFORMATION CONTACT:

Additional information may be obtained from Dr. Mary L. Ganikos, at the address above or via the following contact information: telephone—(301) 443—7577; fax—(301) 443—1267; or e-mail—mganikos@hrsa.gov.

Dated: May 16, 2000.

Claude Earl Fox,

Administrator.

[FR Doc. 00–12752 Filed 5–19–00; 8:45 am]

BILLING CODE 4160-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration Advisory Council; Notice of Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Public Law 92–463), announcement is made of the following National Advisory body scheduled to meet during the month of June 2000.

Name: Maternal and Child Health Research Grants Review Committee.

Date and Time: June 14–16, 2000; 8 a.m.–5 p.m.

Place: Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852.